These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The FDA, contraceptive marketing approval and products liability litigation: Depo-Provera and the risk of osteoporosis. Green W Food Drug Law J; 2013; 68(2):115-35, i. PubMed ID: 24640465 [TBL] [Abstract][Full Text] [Related]
4. Injectable hormones and regulatory controversy: an end to the long-running story? Klitsch M Fam Plann Perspect; 1993; 25(1):37-40. PubMed ID: 8432375 [TBL] [Abstract][Full Text] [Related]
5. Depo-Provera: an injectable contraceptive. Earl DT; David DJ Am Fam Physician; 1994 Mar; 49(4):891-4, 897-8. PubMed ID: 8116522 [TBL] [Abstract][Full Text] [Related]
6. Depo-Provera use in an Australian metropolitan practice. Fraser IS; Dennerstein GJ Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553 [TBL] [Abstract][Full Text] [Related]
7. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant. Harel Z; Biro FM; Kollar LM; Rauh JL J Adolesc Health; 1996 Aug; 19(2):118-23. PubMed ID: 8863083 [TBL] [Abstract][Full Text] [Related]
9. Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Jain J; Dutton C; Nicosia A; Wajszczuk C; Bode FR; Mishell DR Contraception; 2004 Jul; 70(1):11-8. PubMed ID: 15208047 [TBL] [Abstract][Full Text] [Related]
11. Depo-provera in the First World. McDonough RT Hastings Cent Rep; 1988; 18(4):44-5. PubMed ID: 2975641 [No Abstract] [Full Text] [Related]
12. Not FDA-approved, but experts recommend Depo-Provera. Contracept Technol Update; 1992 Jan; 13(1):1-7. PubMed ID: 12343458 [TBL] [Abstract][Full Text] [Related]
13. Contraceptive efficacy and safety of DMPA-SC. Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329 [TBL] [Abstract][Full Text] [Related]
14. In favor of continued use of depot medroxyprogesterone acetate (DMPA, Depo-Provera) in adolescents. Cromer B J Pediatr Adolesc Gynecol; 2005 Jun; 18(3):183-7. PubMed ID: 15970253 [No Abstract] [Full Text] [Related]
15. Why women quit using Depo-Provera? Tinkle M; Reifsnider E; Ransom SP AWHONN Lifelines; 2001 Dec-2002 Jan; 5(6):36-41. PubMed ID: 11778463 [No Abstract] [Full Text] [Related]
16. New year, new option: Cyclo-Provera awaits word. Contracept Technol Update; 1998 Jan; 19(1):3-4. PubMed ID: 12348212 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia. Sobande AA; Al-Bar HM; Archibong EI; Sadek AA Saudi Med J; 2000 Apr; 21(4):348-51. PubMed ID: 11533816 [TBL] [Abstract][Full Text] [Related]